Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • B cells

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Lilly reports survival benefit with Verzenio in high-risk early breast cancer

    The findings are based on Lilly’s phase 3 monarchE trial

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    - PMLiVE

    Researchers uncover promising treatment approach for inherited breast cancer

    The study evaluated chemotherapy followed by a targeted cancer drug in patients before surgery

    - PMLiVE

    Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

    Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

    - PMLiVE

    AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

    Around one in three patients with early-stage breast cancer are considered high risk

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

    Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

    - PMLiVE

    AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

    NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links